Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of -0.42 is 137% below its 5-year average of 1.12, around the middle of its 5-year range (-32.45–18.69).
As of the fiscal period ended Tuesday, June 30, 2026. 79.59% above its 12-month average of -2.04.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): -0.42.
DEBT TO EQUITY RATIO
-0.42
DEBT TO EQUITY RATIO AVG TTM
-2.04
DEBT TO EQUITY RATIO AVG 3Y
1.06
DEBT TO EQUITY RATIO AVG 5Y
1.12
DEBT TO EQUITY RATIO AVG 10Y
0.51
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+79.59%
CURRENT VS 3Y AVG
-139.38%
CURRENT VS 5Y AVG
-137.27%
CURRENT VS 10Y AVG
-181.17%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.14
median of 516 covered companies
CURRENT VS SECTOR MEDIAN
-408.05%
vs the sector median at left
Gossamer Bio, Inc.
Market Cap
$64.80M
Debt to Equity Ratio
-0.42
TTM Avg
-2.04
3Y Avg
1.06
5Y Avg
1.12
Market Cap
$64.83M
Debt to Equity Ratio
0.02
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.03
Market Cap
$64.35M
Debt to Equity Ratio
21.48
TTM Avg
9.81
3Y Avg
10.71
5Y Avg
5.89
Market Cap
$67.43M
Debt to Equity Ratio
0.39
TTM Avg
2.42
3Y Avg
2.91
5Y Avg
2.20
Market Cap
$67.67M
Debt to Equity Ratio
N/A
TTM Avg
1.49
3Y Avg
1.10
5Y Avg
0.74
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | $64.80M | -0.42 | -2.04 | 1.06 | 1.12 |
| Cingulate Inc. (CING)vs › | $65.06M | 0.27 | 2.09 | 1.90 | 1.47 |
| Alps Group Inc (ALPS)vs › | $64.06M | N/A | 0.32 | 0.11 | 0.11 |
| Kalaris Therapeutics Inc (KLRS)vs › | $64.83M | 0.02 | 0.01 | 0.01 | 0.03 |
| InterCure Ltd. (INCR)vs › | $63.02M | 0.46 | 0.49 | 0.48 | 0.36 |
| Heron Therapeutics, Inc. (HRTX)vs › | $64.35M | 21.48 | 9.81 | 10.71 | 5.89 |
| Fortress Biotech, Inc. (FBIO)vs › | $67.43M | 0.39 | 2.42 | 2.91 | 2.20 |
| PDS Biotechnology Corporation (PDSB)vs › | $67.67M | N/A | 1.49 | 1.10 | 0.74 |
| iBio, Inc. (IBIO)vs › | $68.60M | 0.03 | 0.14 | 0.40 | 0.38 |
| Champions Oncology, Inc. (CSBR)vs › | $69.33M | 2.82 | 1.39 | 1.54 | 1.39 |
Debt/Equity
-0.42
Current Ratio
0.53
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | -0.42 |
| 2026-03-31 | -1.26 |
| 2025-12-31 | -1.65 |
| 2025-09-30 | -2.46 |
| 2025-06-30 | -4.40 |
| 2025-03-31 | -32.45 |
| 2024-12-31 | 6.88 |
| 2024-09-30 | 3.76 |
| 2024-06-30 | 2.44 |
| 2024-03-31 | 7.82 |
| 2023-12-31 | 3.38 |
| 2023-09-30 | 2.06 |
| 2023-06-30 | -3.49 |
| 2023-03-31 | -7.82 |
| 2022-12-31 | 18.69 |
| 2022-09-30 | 4.06 |
| 2022-06-30 | -14.11 |
| 2022-03-31 | 7.72 |
| 2021-12-31 | 1.53 |
| 2021-09-30 | 1.09 |
| 2021-06-30 | 0.84 |
| 2021-03-31 | 0.68 |
| 2020-12-31 | 0.57 |
| 2020-09-30 | 0.49 |
| 2020-06-30 | 0.43 |
| 2020-03-31 | 0.13 |
| 2019-12-31 | 0.11 |
| 2019-09-30 | 0.10 |
| 2019-06-30 | -0.18 |
| 2019-03-31 | 0.03 |
| 2018-12-31 | 0.00 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | -0.88 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
